"Sirolimus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.
| Descriptor ID |
D020123
|
| MeSH Number(s) |
D02.540.505.760
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sirolimus".
Below are MeSH descriptors whose meaning is more specific than "Sirolimus".
This graph shows the total number of publications written about "Sirolimus" by people in this website by year, and whether "Sirolimus" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 3 | 3 |
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 1 | 2 |
| 2003 | 1 | 1 | 2 |
| 2004 | 2 | 1 | 3 |
| 2005 | 1 | 1 | 2 |
| 2006 | 2 | 1 | 3 |
| 2007 | 3 | 1 | 4 |
| 2008 | 4 | 4 | 8 |
| 2009 | 6 | 1 | 7 |
| 2010 | 3 | 7 | 10 |
| 2011 | 7 | 2 | 9 |
| 2012 | 4 | 8 | 12 |
| 2013 | 4 | 6 | 10 |
| 2014 | 8 | 2 | 10 |
| 2015 | 5 | 6 | 11 |
| 2016 | 4 | 4 | 8 |
| 2017 | 4 | 3 | 7 |
| 2018 | 2 | 4 | 6 |
| 2019 | 2 | 2 | 4 |
| 2020 | 0 | 5 | 5 |
| 2021 | 2 | 3 | 5 |
| 2022 | 1 | 7 | 8 |
| 2023 | 0 | 2 | 2 |
| 2024 | 4 | 2 | 6 |
| 2025 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sirolimus" by people in Profiles.
-
Sirolimus in the Management of Complex Infantile Hemangiomas: A State-of-the-Art Review. Pediatr Dermatol. 2025 Nov-Dec; 42(6):1126-1132.
-
Sirolimus utilization in pediatric liver transplantation: A large high-volume quaternary center experience. J Pediatr Gastroenterol Nutr. 2025 Aug; 81(2):167-176.
-
Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial. Lancet. 2025 04 26; 405(10488):1481-1490.
-
A Phase 1 Study of ABI-009 (Nab-sirolimus) in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors-A Children's Oncology Group Pediatric Early Phase Clinical Trial Network Study ADVL1514. Cancer Med. 2024 Nov; 13(21):e70376.
-
Ex Utero Intrapartum Treatment for Prenatally Diagnosed Cervicofacial Lymphatic Malformations. J Surg Res. 2024 11; 303:628-635.
-
Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group. Lancet Oncol. 2024 07; 25(7):912-921.
-
Controlled Delivery of Rosuvastatin or Rapamycin through Electrospun Bismuth Nanoparticle-Infused Perivascular Wraps Promotes Arteriovenous Fistula Maturation. ACS Appl Mater Interfaces. 2024 07 03; 16(26):33159-33168.
-
Sirolimus for vascular anomalies in the first year of life: a systematic review. J Perinatol. 2024 Aug; 44(8):1087-1097.
-
TFEB drives mTORC1 hyperactivation and kidney disease in Tuberous Sclerosis Complex. Nat Commun. 2024 01 09; 15(1):406.
-
mTORC1 regulates the metabolic switch of postnatal cardiomyocytes during regeneration. J Mol Cell Cardiol. 2024 02; 187:15-25.